Eli Lilly Launches Revolutionary Website LillyDirect to Offer Weight Loss Drugs through Telehealth Service

John Smith

Eli Lilly has launched a website called LillyDirect that will allow patients to get a weight loss drug prescription through a telehealth service. The website will connect patients with the telehealth provider Form Health, whose obesity medicine doctors will work with patients to determine whether a prescription is appropriate.

The website is intended for people who currently meet certain criteria, including a BMI of at least 30 or a BMI of at least 27 with at least one weight-related medical condition. The website will offer access to popular and effective drugs, including Eli Lilly’s recently approved drug, Zepbound.

The launch of this website has hurt the stocks of companies like Weight Watchers and LifeMD, which also offer weight loss drugs through online platforms.

Eli Lilly’s Weight Loss Drug

Eli Lilly’s weight loss drug is called tirzepatide. It is a weekly injection that has shown promising results in helping patients lose weight, with an average weight reduction of about 26% in late-stage trials.

This makes it one of the most effective weight loss drugs in late-stage clinical trials to date. The drug works by changing the way patients eat and leading to a decreased appetite.

It mimics the effects of certain hunger-regulating hormones, making it a popular and effective option in the weight loss drug market.

How Does Eli Lilly’s Telehealth Service Work

LillyDirect, a telehealth service operated by Eli Lilly, enables patients to obtain prescriptions for weight loss medications via telehealth. Patients are connected via the website to the telehealth provider Form Health, whose physicians specializing in obesity medicine collaborate with patients to ascertain the suitability of prescriptions.

The website is accessible to patients who satisfy specific requirements, such as having a BMI of 30 or higher or a BMI of 27 or higher in conjunction with at least one weight-related medical condition. Once per month, patients who are prescribed a weight loss medication will conduct a virtual consultation with their physician.

Physicians will have the autonomy to prescribe any weight reduction medication approved by the FDA; however, eligibility for Lilly’s at-home prescription delivery will be restricted to those who are already prescribed Zepbound.

What is the Market Share of Eli Lilly’s Weight Loss Drugs Compared to Other Companies

Eli Lilly’s weight loss drugs are poised to capture a significant share of the market, with the obesity drug market forecasted to reach $100 billion by 2030. Analysts at J.P. Morgan predict that Eli Lilly could achieve $50 billion in annual sales from weight loss drugs by 2030, making it a major player in the industry.

The company’s GLP-1 drug, Zepbound, is expected to dominate the weight loss market, with a surge in prescriptions and a 192% increase in weekly prescription writings. This growth suggests that Eli Lilly’s weight loss drugs are gaining market share, potentially taking market share from competitors like Novo Nordisk.

Fundamental Analysis of Eli Lilly

Revenue Growth (YOY)1.66%
Earnings Growth (YOY)1.87%
Return on Equity6.00%
Return on Assets3.56%
Debt to Equity Ratio0.62
Market Capitalization$106.54 billion
Eli Lilly’s Weight Loss Drug Market Share0% (as of 2023)

Eli Lilly Shareholding Pattern

Shareholder% Holding
Institutional Investors57.81%
Retail Investors20.87%

Eli Lilly’s Stock Financial Condition for the Last 5 Years

Sales/Revenue (USD Millions)28,54128,31824,54022,32021,493
Sales/Revenue Growth0.79%15.40%9.95%3.84%
EBITDA (USD Billions)9.807.096.165.475.08
EBITDA Growth38.05%15.26%12.16%7.68%
Net Income (USD Millions)6,2455,5826,1949573,069
Net Income Growth12.75%-9.80%-23.65%184.33%
Return on Equity63.63%52.36%60.23%10.83%34.08%
Debt to Equity Ratio0.620.570.570.570.57
Market Capitalization (USD Billions)106.54191.22187.68146.68121.68
Note: The data for 2023 is as of the third quarter

Share This Article
John Smith is a veteran stock trader with over 10 years of experience in the financial markets. He is a widely followed market commentator known for his astute analysis and accurate predictions. John has authored multiple bestselling books explaining complex market concepts in simple terms for novice investors looking to grow their wealth through strategic trading and long-term investments.
Leave a comment